| abstract |
The present invention, is well suited for mRNA production for the in vivo (in vivo) therapeutic purposes to an improved RNA transfer vector. This improvement in the vector is due to the presence of translation enhancers (TEs) and nuclear retention sequences (NRSs), particularly when the latter is the "expression and nuclear retention component" (ENE) of Kaposi's sarcoma herpes virus (KSHV). it is by |